<DOC>
	<DOC>NCT01588951</DOC>
	<brief_summary>The primary objective of the trial is to compare the two-year relapse-free survival (RFS) of patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to the presence of leukemia stem cells (LSCs) in their bone marrow at first complete remission (CR1), who receive either standard cytarabine-based chemotherapy or allogeneic stem cell transplantation (SCT).</brief_summary>
	<brief_title>Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1. Age greater than or equal to 18 years 2. Able to give informed consent 3. New diagnosis of AML, other than APL or poorrisk AML, as defined in section 3.2 Exclusion criteria: 1. Has already had a bone marrow biopsy and aspirate to assess remission status after induction therapy 2. Any debilitating medical or psychiatric illness that would preclude ability to give informed consent or receive optimal treatment and followup 3. Pregnancy: Women of childbearing potential who are Î² HCG+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>